GBR 1302

Drug Profile

GBR 1302

Alternative Names: GBR-1302; HER2xCD3 bispecific antibody - Glenmark

Latest Information Update: 09 Jan 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Glenmark Pharmaceuticals S.A.
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD3 antigen modulators; ERBB 2 receptor modulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 03 Jan 2017 US FDA approves IND application for GBR 1302 in HER2 positive cancer
  • 04 Nov 2016 Pharmacodynamics data from preclinical studies in Cancer were presented at European Society of Medical Oncology Symposium (ESMO-2016)
  • 01 May 2016 Phase-I clinical trials in HER2 positive Cancer in Germany (Parenteral) (NCT02829372)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top